Loading Events

« All Events

  • This event has passed.

New England Healthcare Executive Meeting

December 5, 2016 @ 7:30 am - 10:00 am

$40 - $55

THE HUMAN MICROBIOME: IS IT THE PANACEA FOR CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASE?

Program Description:

The microbiome is the focus of many researchers interested in how ecological community of commensal, symbiotic and pathogenic microorganisms interact with our immune systems and contribute to the rise of multiple disorders. This research could have profound therapeutic implications in the treatment of cancer, diabetes, autoimmune and inflammatory disease.

  • But what does this disruptive technology really mean for healthcare?
  • Will engineered probiotic bacteria correct missing or dysfunctional metabolic activities throughout the body?
  • Human Microbiome Project Initiative – what can Federal involvement due to enable research?
  • What opportunities are there to develop new therapeutics for patients across multiple disease areas?
  • Do inflammatory microbes in our gut increase our risk for diabetes and autoimmune disorders and can intervention prevent these diseases?
  • What can we learn from the hygiene hypothesis and modify our lifestyles and live longer?
  • Will therapeutic options for care lead to lower cost and improved patient outcomes?

Come join this timely, lively, blue ribbon panel of experts. Ask them questions and contribute your insights during the audience interactive segment.

Keynote Speaker:

James J. Collins, Ph.D., Termeer Professor of Medical Engineering & Science, Professor, Department of Biological Engineering Massachusetts Institute of Technology

Moderator:

John Brooks, Managing Director, Healthcare Capital

Panelists:

David Barry, General Partner, Flagship Ventures
JC Gutiérrez-Ramos, Ph.D., CEO, Synlogic Therapeutics

Who Should Attend:

CEOs, CTOs, CFOs, clinicians, technologists, investors, and business experts seeking a better understanding of the potential of the microbiome to change the lives of patients.

Biographies:

David Berry, General Partner, Flagship Ventures
David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability. He is a founder of Flagship portfolio companies Joule Unlimited, Eleven Biotherapeutics (NASDAQ: EBIO), Seres Therapeutics (NASDAQ: MCRB), Axcella Health, LS9 (acquired by Renewable Energy Group) and Indigo. David has served as founding CEO of Joule, Axcella Health and Seres. He currently serves on the boards of Eleven, Axcella Health and Avedro. He was previously a Board member of CGI Pharmaceuticals (acquired by Gilead), Joule, Seres and Indigo.

Prior to Flagship, David received an MD from Harvard Medical School and a PhD from the MIT Biological Engineering Division, working in the laboratories of Professors Ram Sasisekharan and Bob Langer, completing the dual degree in just over 5 years.

David currently serves on the Leadership Council of the United Nations Sustainable Development Solutions Network. He is currently on the Boards of the Hackley School and the Juventas New Music Ensemble, and has served on the MIT Corporation, its Board of Trustees as well as the Boston Philharmonic Orchestra.

David was elected a 2014 Young Global Leader by the World Economic Forum. Previously, David was named the Innovator of the Year by Technology Review, and received the prestigious Lemelson-MIT Student Prize for invention and innovation. He was also selected by the US State Department as 1 of 12 Innovators Helping to Reshape Reality.

John L. Brooks III is the Managing Director of Healthcare Capital LLC
Mr. Brooks advises early-stage life sciences companies. Healthcare Capital specializes in advancing disruptive and innovative solutions in healthcare, especially in obesity, pre-diabetes, and diabetes. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations.

Mr. Brooks is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.

Mr. Brooks is a well-known life sciences executive. He has co-founded seven life sciences companies, including Insulet (PODD), a disruptive insulin delivery company. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm.

James J. Collins, Ph.D., Termeer Professor of Medical Engineering & Science, Professor, Department of Biological Engineering Massachusetts Institute of Technology
James J. Collins is Termeer Professor of Bioengineering in the Department of Biological Engineering and Institute for Medical Engineering & Science. He is also affiliated with the Broad Institute and the Wyss Institute. His research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance. Professor Collins’ patented technologies have been licensed by over 25 biotech, pharma and medical devices companies, and he has helped to launched a number of companies, including Sample6 Technologies, Synlogic and EnBiotix. He has received numerous awards and honors, including a Rhodes Scholarship, a MacArthur “Genius” Award, an NIH Director’s Pioneer Award, a Sanofi-Institut Pasteur Award, as well as several teaching awards. Professor Collins is an elected member of the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the American Academy of Arts & Sciences, and a charter fellow of the National Academy of Inventors.

The Collins research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance.

JC Gutiérrez-Ramos, Ph.D., CEO, Synlogic Therapeutics
Dr. Gutiérrez-Ramos joins Synlogic from Pfizer, where he served as Group Senior Vice President and global head of the BioTherapeutics Research. In that role, he held responsibility for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. He oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. He previously held the position of Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc) into therapeutics. Prior to his work in the pharmaceutical industry, JC held senior leadership positions at several biotech companies; He was Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc. where he led a significant efforts focused on the discovery of novel protein therapeutics and peptides for autoimmune disease, including multiple sclerosis and diabetes. He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery. In that capacity he was responsible for advancing preclinical candidates in inflammation and immunology into human clinical trials and advancing compounds (small molecules and antibodies) from discovery through clinical development. JC began his career in academia as part of the Faculty at the Genetics department of Harvard Medical School. He was member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Plank Institute in Freiburg, Germany. He has co-authored more than 150 peer-reviewed publications. JC holds a PhD in immunochemistry from the Autonoma University in Madrid, Spain.

Details

Date:
December 5, 2016
Time:
7:30 am - 10:00 am
Cost:
$40 - $55
Website:
https://www.eventbrite.com/e/the-human-microbiome-tickets-28660876453

Venue

FOLEY HOAG LLP
Seaport West, 155 Seaport Boulevard
Boston,02210
+ Google Map

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow us!

Send this to a friend